Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT)
CUSIP: 45258J102
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 202,731,676
- Total 13F shares
- 108,607,774
- Share change
- +13,570,331
- Total reported value
- $2,761,164,222
- Put/Call ratio
- 19%
- Price per share
- $25.42
- Number of holders
- 194
- Value change
- +$365,946,432
- Number of buys
- 105
- Number of sells
- 78
Quarterly Holders Quick Answers
What is CUSIP 45258J102?
CUSIP 45258J102 identifies IMVT - Immunovant, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 45258J102:
Top shareholders of IMVT - Immunovant, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. |
13D/G
3/4/5
|
Director, 10%+ Owner |
56%
|
113,327,007
|
$2,812,776,314 | +$413,666,650 | 12 Dec 2025 | |
| FMR LLC |
13D/G
13F
|
Company |
8.4%
|
14,729,555
|
$237,440,423 | -$37,858,433 | 30 Sep 2025 | |
| Deep Track Capital, LP |
13F
13D/G
|
Company |
5.6%
from 13D/G
|
9,728,845
|
$156,828,981 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.4%
|
6,826,810
|
$110,048,178 | — | 30 Sep 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
2.9%
|
5,836,000
|
$94,076,320 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
2.8%
|
5,738,236
|
$92,500,364 | — | 30 Sep 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
2.7%
|
5,457,881
|
$87,981,042 | — | 30 Sep 2025 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
2.5%
|
5,164,698
|
$83,255,000 | — | 30 Sep 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.7%
|
3,442,078
|
$55,486,307 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.4%
|
2,892,618
|
$46,629,002 | — | 30 Sep 2025 | |
| Two Seas Capital LP |
13F
|
Company |
1.4%
|
2,762,040
|
$44,524,085 | — | 30 Sep 2025 | |
| Alpine Global Management, LLC |
13F
|
Company |
1.4%
|
2,754,731
|
$44,406,264 | — | 30 Sep 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
1.1%
|
2,241,753
|
$36,137,058 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.97%
|
1,959,026
|
$31,579,516 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.89%
|
1,801,649
|
$29,047,160 | — | 30 Sep 2025 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.78%
|
1,589,580
|
$25,624,030 | — | 30 Sep 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.78%
|
1,587,890
|
$25,596,787 | — | 30 Sep 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.74%
|
1,498,725
|
$24,159,447 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.73%
|
1,482,539
|
$23,898,528 | — | 30 Sep 2025 | |
| Peter Salzmann |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
1,552,586
mixed-class rows
|
$17,543,264 | — | 16 Apr 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.48%
|
981,804
|
$15,826,680 | — | 30 Sep 2025 | |
| Julia G. Butchko |
3/4/5
|
Chief Development Officer |
—
mixed-class rows
|
509,682
mixed-class rows
|
$14,251,795 | — | 21 Aug 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.37%
|
746,553
|
$12,034,434 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.36%
|
726,173
|
$11,705,908 | — | 30 Sep 2025 | |
| Prosight Management, LP |
13F
|
Company |
0.34%
|
698,472
|
$11,259,369 | — | 30 Sep 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.34%
|
683,402
|
$11,016,440 | — | 30 Sep 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.33%
|
676,577
|
$10,906,421 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.29%
|
580,696
|
$9,360,820 | — | 30 Sep 2025 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.28%
|
558,897
|
$9,009,420 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.27%
|
555,915
|
$8,961,350 | — | 30 Sep 2025 | |
| Mark S. Levine |
3/4/5
|
Chief Legal Officer |
—
mixed-class rows
|
387,951
mixed-class rows
|
$8,124,353 | — | 20 Nov 2024 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
0.25%
|
500,000
|
$8,060,000 | — | 30 Sep 2025 | |
| William L. Macias |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
426,076
mixed-class rows
|
$7,454,384 | — | 19 Feb 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.22%
|
448,051
|
$7,222,582 | — | 30 Sep 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.21%
|
419,680
|
$6,765,242 | — | 30 Sep 2025 | |
| CANADA PENSION PLAN INVESTMENT BOARD |
13F
|
Company |
0.2%
|
414,800
|
$6,686,576 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.18%
|
374,769
|
$6,041,274 | — | 30 Sep 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.18%
|
374,285
|
$6,033,433 | — | 30 Sep 2025 | |
| Eva Renee Barnett |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
521,954
mixed-class rows
|
$5,907,965 | — | 16 Apr 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.17%
|
343,600
|
$5,538,832 | — | 30 Sep 2025 | |
| SUPERSTRING CAPITAL MANAGEMENT LP |
13F
|
Company |
0.17%
|
341,348
|
$5,502,530 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.17%
|
337,666
|
$5,443,176 | — | 30 Sep 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.15%
|
300,000
|
$4,836,000 | — | 30 Sep 2025 | |
| Jump Financial, LLC |
13F
|
Company |
0.15%
|
296,260
|
$4,775,711 | — | 30 Sep 2025 | |
| Logos Global Management LP |
13F
|
Company |
0.14%
|
275,000
|
$4,433,000 | — | 30 Sep 2025 | |
| Granahan Investment Management, LLC |
13F
|
Company |
0.13%
|
266,221
|
$4,291,483 | — | 30 Sep 2025 | |
| Michael Geffner |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
361,021
mixed-class rows
|
$4,147,740 | -$133,403 | 22 Oct 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.13%
|
256,743
|
$4,138,697 | — | 30 Sep 2025 | |
| HighVista Strategies LLC |
13F
|
Company |
0.12%
|
253,127
|
$4,080,408 | — | 30 Sep 2025 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.12%
|
252,712
|
$4,073,712 | — | 30 Sep 2025 |
Institutional Holders of Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT) as of Q4 2025
As of 31 Dec 2025,
Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT) was held by
194 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
108,607,774 shares.
The largest 10 holders included
FMR LLC, Deep Track Capital, LP, VANGUARD GROUP INC, BlackRock, Inc., ARMISTICE CAPITAL, LLC, BAKER BROS. ADVISORS LP, T. Rowe Price Investment Management, Inc., MORGAN STANLEY, STATE STREET CORP, and RTW INVESTMENTS, LP.
This page lists
194
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
183
Q4 2025 holders
194
Holder diff
11
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.